Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: J Immunol. 2013 Feb 6;190(6):2984–2993. doi: 10.4049/jimmunol.1201650

Figure 4. TAM alternative activation profile and phenotype is attenuated by MIF-deficiency and 4-IPP treatment.

Figure 4

(A, C) F4/80+ TAMs from MIF+/+ and MIF−/− C57BL/6 mice (n = 10) bearing a s.c. melanoma tumor were pooled and activated in vitro with (A) LPS alone or (C) LPS in the presence of either DMSO (vehicle control) or 4-IPP (50 μM) for 24 hours. Cell lysates were analyzed for mRNA, protein expression and arginase activity. (B, D) F4/80+ TAMs from tumor-bearing MIF+/+ and MIF−/− C57BL/6 mice (n = 10) were untreated or pre-treated for 16 hours with 4-IPP (50 μm) or DMSO (vehicle control). Splenocytes from OT-1 mice were added in triplicate to wells containing TAMs in the presence of ovalbumin (200 μg/ml) and cultured for 72 hours. Eighteen hours before harvesting, co-cultures were pulsed with [3H]-thymidine. Data represents the average ± SEM of duplicate samples (A, C) or average ± SD of triplicate samples (B, D) representative of three independent experiments. P values = *, p≤0.05; **, p≤0.005; ***, p≤0.0005.